{"id":"cpk-dosage","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CPK works by binding to its receptor, which triggers a cascade of signaling events that promote the proliferation and differentiation of epithelial cells. This leads to the regeneration of damaged epithelial tissues. The exact molecular mechanisms underlying CPK's effects are complex and not fully understood.","oneSentence":"CPK is a recombinant human keratinocyte growth factor used to stimulate epithelial regeneration.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:31.615Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mucositis prevention in patients undergoing chemotherapy"}]},"trialDetails":[{"nctId":"NCT01248429","phase":"","title":"Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2010-11","conditions":"Cancer, Solid Tumor","enrollment":154},{"nctId":"NCT03374657","phase":"PHASE1, PHASE2","title":"A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-22","conditions":"Retinitis Pigmentosa","enrollment":12},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06812221","phase":"PHASE1, PHASE2","title":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-12-15","conditions":"Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder","enrollment":20},{"nctId":"NCT06910098","phase":"NA","title":"Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels","status":"COMPLETED","sponsor":"Central Park Medical College","startDate":"2023-12-01","conditions":"LDL - Low Density Lipoprotein Receptor Disorder, Rosuvastatin","enrollment":195},{"nctId":"NCT06816667","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-10-21","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT06511960","phase":"NA","title":"Effects of Astaxanthin Supplementation","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2023-09-01","conditions":"Dietary Supplements","enrollment":24},{"nctId":"NCT02463305","phase":"EARLY_PHASE1","title":"Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2022-08","conditions":"Colitis, Ulcerative","enrollment":""},{"nctId":"NCT02746718","phase":"NA","title":"Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-12-11","conditions":"Pompe Disease","enrollment":50},{"nctId":"NCT04723602","phase":"PHASE1","title":"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2021-01-06","conditions":"Ebola Virus Disease, Marburg Virus Disease","enrollment":32},{"nctId":"NCT03961503","phase":"","title":"Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-01-01","conditions":"Infective Endocarditis, Infection Related to Ventricular Assist Device, Infection Related to Vascular Prothesis","enrollment":72},{"nctId":"NCT03163719","phase":"","title":"Impact of Early Lactate Dosage Compared to CK for Diagnosis of a Suspected Seizure","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2016-11-28","conditions":"Epileptic Seizure, Creatine Kinase, Lactate","enrollment":100},{"nctId":"NCT00656292","phase":"PHASE4","title":"Assessing the Role of \"Statin\" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-04","conditions":"Perioperative Inflammatory Response","enrollment":61},{"nctId":"NCT01971723","phase":"NA","title":"Multi-ingredient Supplement for Strength and Power","status":"COMPLETED","sponsor":"Florida State University","startDate":"2013-06","conditions":"Supplement","enrollment":32},{"nctId":"NCT01561482","phase":"PHASE2","title":"Study of Metformin With Simvastatin for Men With Prostate Carcinoma","status":"WITHDRAWN","sponsor":"Nicholas Mitsiades","startDate":"2012-01","conditions":"Prostate Carcinoma","enrollment":""},{"nctId":"NCT01925079","phase":"NA","title":"Intensive Education on Lipid Management","status":"UNKNOWN","sponsor":"Junbo Ge","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":2568},{"nctId":"NCT00615823","phase":"PHASE2","title":"Atorvastatin in Pulmonary Hypertension","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2007-02","conditions":"Hypertension, Pulmonary","enrollment":220}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CPK dosage","genericName":"CPK dosage","companyName":"Centre Oscar Lambret","companyId":"centre-oscar-lambret","modality":"Biologic","firstApprovalDate":"","aiSummary":"CPK is a recombinant human keratinocyte growth factor used to stimulate epithelial regeneration. Used for Mucositis prevention in patients undergoing chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}